{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T10:38:13Z","timestamp":1789814293775,"version":"4.0.1"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001794","name":"University of Queensland Scholarship","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Serious Gram-negative bacterial infections impose significant burden, with carbapenem-resistant Acinetobacter baumannii and carbapenem-resistant Enterobacterales designated as WHO critical priority pathogens. Antibacterial registration trials are traditionally stand-alone two-arm randomized controlled trials evaluating one agent in a site-specific infection. Platform trials have been proposed as an alternative to identify new treatments more efficiently.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the efficiency of different trial designs for treatments in serious resistant Gram-negative infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted simulation studies comparing platform trials with parallel and staggered starts and multiple stand-alone trials for serious infections caused by critical priority Gram-negative pathogens. Simulated recruitment and randomization were used to assess the impact of trial design, control type and allocation ratio on trial duration, sample size and operating characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In this setting, parallel or staggered platform trials reduced the sample size by 31\u2013279 participants and the trial duration by 7\u201313\u2005months compared with stand-alone trials. The staggered platform trial with concurrent controls required 11.0%\u201323.4% fewer participants and up to 46.8% less control participants than stand-alone trials. Across designs and scenarios, type I error and power, were consistently close to the nominal levels for all treatment-control comparisons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Platform trials can improve efficiency over stand-alone trials, reducing duration and sample size while maintaining operating characteristics. The improvement varies with control type, allocation ratio and staggered entry of agents and could help accelerate antibacterial development. This has implications for funders, sponsors and patients requiring access to new therapies, while recognizing ongoing operational and regulatory challenges.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag263","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:45:23Z","timestamp":1784288723000},"source":"Crossref","is-referenced-by-count":1,"title":["Evaluating the efficiency of platform trials relative to stand-alone trials: a simulation study for the evaluation of new antibacterials"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2427-6082","authenticated-orcid":false,"given":"Melissa J","family":"Hardy","sequence":"first","affiliation":[{"name":"Faculty of Health, Medicine and Behavioural Sciences, Frazer Institute, University of Queensland , Brisbane ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2895-0345","authenticated-orcid":false,"given":"Patrick N A","family":"Harris","sequence":"additional","affiliation":[{"name":"Faculty of Health, Medicine and Behavioural Sciences, Frazer Institute, University of Queensland , Brisbane ,","place":["Australia"]},{"name":"Central Microbiology Laboratory, Pathology Queensland , Brisbane ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology and Biostatistics Unit, Murdoch Children's Research Institute , Melbourne ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0216-9550","authenticated-orcid":false,"given":"Yin","family":"Mo","sequence":"additional","affiliation":[{"name":"ADVANCE-ID, Saw Swee Hock School of Public Health, National University of Singapore , 12 Science Drive 2, #10-01, Singapore 117549 ,","place":["Singapore"]},{"name":"Infectious Diseases Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore ,","place":["Singapore"]},{"name":"Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford , Oxford ,","place":["UK"]},{"name":"Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University , Bangkok ,","place":["Thailand"]},{"name":"Division of Infectious Diseases, University Medicine Cluster, National University Hospital ,","place":["Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L","family":"Paterson","sequence":"additional","affiliation":[{"name":"ADVANCE-ID, Saw Swee Hock School of Public Health, National University of Singapore , 12 Science Drive 2, #10-01, Singapore 117549 ,","place":["Singapore"]},{"name":"Infectious Diseases Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore ,","place":["Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"2026080410211474000_dkag263-B1","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990\u20132021: a systematic analysis with forecasts to 2050","volume":"404","author":"Naghavi","year":"2024","journal-title":"Lancet"},{"key":"2026080410211474000_dkag263-B2","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S1473-3099(25)00118-5","article-title":"The WHO bacterial priority pathogens list 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance","volume":"25","author":"Sati","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026080410211474000_dkag263-B3","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/13543784.2024.2326028","article-title":"Antibacterial agents active against gram negative Bacilli in phase I, II, or III clinical trials","volume":"33","author":"Paterson","year":"2024","journal-title":"Expert Opin Investig Drugs"},{"key":"2026080410211474000_dkag263-B4","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1056\/NEJM198212233072604","article-title":"Double standards, scientific methods, and epidemiologic research","volume":"307","author":"Feinstein","year":"1982","journal-title":"N Engl J Med"},{"key":"2026080410211474000_dkag263-B5","doi-asserted-by":"publisher","first-page":"S126","DOI":"10.1093\/cid\/ciag017","article-title":"Antibiotic clinical trials: a review of the past, present challenges and potential solutions","volume":"82","author":"Hardy","year":"2026","journal-title":"Clin Infect Dis"},{"key":"2026080410211474000_dkag263-B6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2026080410211474000_dkag263-B7","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2026080410211474000_dkag263-B8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2026080410211474000_dkag263-B9","doi-asserted-by":"publisher","first-page":"e4539","DOI":"10.1093\/cid\/ciaa803","article-title":"A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem\/cilastatin\/relebactam versus piperacillin\/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 study)","volume":"73","author":"Titov","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026080410211474000_dkag263-B10","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","article-title":"Efficacy and safety of sulbactam\u2013durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii\u2013calcoaceticus complex: a multicentre, randomized, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2026080410211474000_dkag263-B11","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.cmi.2023.09.024","article-title":"Evaluating the innovative potential of the global antibacterial pipeline","volume":"31","author":"Theuretzbacher","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"2026080410211474000_dkag263-B12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/cid\/cix726","article-title":"Cost drivers of a hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia phase 3 clinical trial","volume":"66","author":"Stergiopoulos","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2026080410211474000_dkag263-B13","author":"President\u2019s Council of Advisors on Science and Technology"},{"key":"2026080410211474000_dkag263-B14","author":"Center for Drug Evaluation and Research F"},{"key":"2026080410211474000_dkag263-B15","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1093\/cid\/ciy516","article-title":"Optimizing the design and analysis of clinical trials for antibacterials against multidrug-resistant organisms: a white paper from COMBACTE\u2019s STAT-net","volume":"67","author":"de Kraker","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2026080410211474000_dkag263-B16","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1002\/sim.8086","article-title":"Using simulation studies to evaluate statistical methods","volume":"38","author":"Morris","year":"2019","journal-title":"Stat Med"},{"key":"2026080410211474000_dkag263-B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jclinepi.2020.04.025","article-title":"An overview of platform trials with a checklist for clinical readers","volume":"125","author":"Park","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"2026080410211474000_dkag263-B18","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1080\/01621459.1955.10501294","article-title":"A multiple comparison procedure for comparing several treatments with a control","volume":"50","author":"Dunnett","year":"1955","journal-title":"J Am Stat Assoc"},{"key":"2026080410211474000_dkag263-B19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/cpt.3244","article-title":"Regulatory issues of platform trials: learnings from EU-PEARL","volume":"116","author":"Nguyen","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"2026080410211474000_dkag263-B20","author":"Aldrich"},{"key":"2026080410211474000_dkag263-B21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jclinepi.2022.11.002","article-title":"An overview of methodological considerations regarding adaptive stopping, arm dropping, and randomization in clinical trials","volume":"153","author":"Granholm","year":"2023","journal-title":"J Clin Epidemiol"},{"key":"2026080410211474000_dkag263-B22","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1056\/NEJMc2102446","article-title":"Platform trials beware the noncomparable control group","volume":"384","author":"Dodd","year":"2021","journal-title":"N Engl J Med"},{"key":"2026080410211474000_dkag263-B23","author":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research"},{"key":"2026080410211474000_dkag263-B24","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1002\/sim.8539","article-title":"Imbalanced randomization in clinical trials","volume":"39","author":"Chandereng","year":"2020","journal-title":"Stat Med"},{"key":"2026080410211474000_dkag263-B25","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026080410211474000_dkag263-B26","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2026080410211474000_dkag263-B27","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S1473-3099(24)00499-7","article-title":"Aztreonam\u2013avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial","volume":"25","author":"Carmeli","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2026080410211474000_dkag263-B28","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1002\/cpt.1804","article-title":"Current statistical considerations and regulatory perspectives on the planning of confirmatory basket, umbrella, and platform trials","volume":"107","author":"Collignon","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"2026080410211474000_dkag263-B29","doi-asserted-by":"publisher","first-page":"e711","DOI":"10.1016\/S2214-109X(20)30542-8","article-title":"How COVID-19 has fundamentally changed clinical research in global health","volume":"9","author":"Park","year":"2021","journal-title":"Lancet Glob Health"},{"key":"2026080410211474000_dkag263-B30","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1158\/1078-0432.CCR-17-0764","article-title":"Adaptive global innovative learning environment for glioblastoma: GBM AGILE","volume":"24","author":"Alexander","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026080410211474000_dkag263-B31","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s12609-019-00334-2","article-title":"I-SPY 2: a neoadjuvant adaptive clinical trial designed to improve outcomes in high-risk breast cancer","volume":"11","author":"Wang","year":"2019","journal-title":"Curr Breast Cancer Rep"},{"key":"2026080410211474000_dkag263-B32","doi-asserted-by":"publisher","first-page":"306","DOI":"10.14283\/jpad.2021.21","article-title":"Platform trials to expedite drug development in Alzheimer\u2019s disease: a report from the EU\/US CTAD task force","volume":"8","author":"Aisen","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"key":"2026080410211474000_dkag263-B33","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1038\/s43587-024-00740-x","article-title":"Lessons from the HEALEY adaptive platform trial in amyotrophic lateral sclerosis","volume":"4","author":"Paganoni","year":"2024","journal-title":"Nat Aging"},{"key":"2026080410211474000_dkag263-B34","doi-asserted-by":"publisher","first-page":"120","DOI":"10.5694\/mja2.52711","article-title":"Platform trials: key features, when to use them and methodological challenges","volume":"223","author":"Mahar","year":"2025","journal-title":"Med J Aust"},{"key":"2026080410211474000_dkag263-B35","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1056\/NEJMsb2517623","article-title":"One pivotal trial, the new default option for FDA approval ending the two-trial dogma","volume":"394","author":"Prasad","year":"2026","journal-title":"N Engl J Med"},{"key":"2026080410211474000_dkag263-B36","author":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/9\/dkag263\/70479310\/dkag263.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/9\/dkag263\/70479310\/dkag263.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:32:53Z","timestamp":1785853973000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag263\/8751016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag263","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,4]]},"article-number":"dkag263"}}